Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Recruiting
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +166 locations
Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Promoting Positive Care Interactions (PPCI) in Assisted Living
Recruiting
The overall aim of this study is to pilot test Promoting Positive Care Interactions (PPCI) with the goal of establishing a feasible and culturally responsive approach to optimize care interactions between staff (nursing, activity, housekeeping, and dining service staff) and residents with ADRD in assisted living facilities (ALFs), and further improve select resident, staff, and facility outcomes. PPCI is a non- pharmacological four-step approach consisting of (1) stakeholder engagement in develo... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/18/2025
Locations: The Pennsylvania State University, University Park, Pennsylvania
Conditions: Alzheimer Disease and Related Dementias
Neurophysiology Biomarkers of Cognitive Impairment Associated with Deep Brain Stimulation
Recruiting
The study aims to investigate cognitive impairment associated with Deep Brain Stimulation (DBS) in Parkinson's Disease patients, with a focus on identifying neurophysiology biomarkers of DBS associated cognitive changes. Using neurophysiology data recorded during DBS surgeries and post-implantation, the research intends to identify biomarkers in order to optimize electrode placement, enhance programming, and ultimately minimize DBS-related cognitive side effects.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
3D Printing to Improve Nasal Irrigation Outcome
Recruiting
Three-dimensional (3D) printing has been an emerging technology with uses in a wide array of fields. This research aims to use 3D printing as a tool to provide personalized education to maximize treatment efficacy based on the patient's individual anatomy. With increased irrigation to the sinuses, we hypothesize there will be improved patient satisfaction and higher quality of life. The outcomes of this research could lead to a new option for patients who live with chronic rhinosinusitis are not... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2025
Locations: The Ohio State University Eye and Ear Institue, Columbus, Ohio
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
TOP 2301: Neoadjuvant Chemo for NSCLC
Recruiting
In this open-label, two-arm, randomized phase 2 clinical trial, patients with clinical stage 1B-3A non-small cell lung cancer (NSCLC) will receive neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks prior to surgery. Eligible patients will be randomized with equal allocation to two treatment groups. Permuted block randomization algorithm will be used for treatment assignment with stratification factors: stage (1B, 2A, 2B, 3A), and performa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Duke University, Durham, North Carolina
Conditions: Non Small Cell Lung Cancer
Wild Blueberries for Gut, Brain, and Heart Health in Adults with High Blood Pressure
Recruiting
The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
03/18/2025
Locations: Georgia State University, Atlanta, Georgia
Conditions: Hypertension (without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Recruiting
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin.... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +228 locations
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Recruiting
Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling. Objective: To study the effects of alirocumab in people who drink alcohol. Eligibility: Healthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week. Design: Participants will be screened under protocol 14-AA-0181... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior
Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels
Recruiting
Acute normovolemic hemodilution (ANH) is performed as a blood conservation technique during surgical procedures with high risk for significant blood loss. It is done by taking out some of the patients blood before surgery actually begins and storing this blood inside of the operating room and giving it back to the patient at the end of surgery when most of the expected surgical bleeding has already occurred. This practice reduces the amount of bleeding that occurs after surgery and also reduces... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/18/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Acute Kidney Injury
Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)
Recruiting
Hypothalamic amenorrhea (HA) occurs during reproductive years and results in stopped menstrual cycles and infertility which can be prolonged from months to years and is characterized by varying combinations of psychosocial stress, anxiety, high levels of physical activity, and/or weight loss. Data from our group indicates that one-third of women with HA (mean age: 27 yrs) have preclinical cardiovascular disease (CVD) measured noninvasively as vascular dysfunction and vascular inflammation. This... Read More
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
03/18/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Hypothalamic Amenorrhea
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment or has not responded to previous treatment (refractory). Multiple myeloma (MM) remains the second most common hematologic malignancy in the United States. A number of therapies have been approved for patients with MM, including CD38... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
Recruiting
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2\* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC. Image acquisition is conducted using a PET/CT machine. \* hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Moffitt Cancer Center, Tampa, Florida +2 locations
Conditions: Pancreatic Cancer